Richard Barfield, chief financial officer of Ergomed PLC talks to Proactive London and explains how the pharma services group continues to beat expectations after more than 30% growth in sales and profits in its latest full year.
A lot of the success is down to “significant tailwinds” in its specialist sectors, such as oncology and rare disease, pharmacovigilance and general pharmaceutical, he says.
Barfield also discusses expansion plans with further acquisitions targeted in the US and Asian markets.
source